The fund is looking for innovative and transformative therapeutics focused on preclinical drug development. The firm is a subsidiary of a foundation, which it can leverage the team at the foundation for venture and investment services, as well as operational support. The firm’s goal is to shepherd promising drug candidates through the riskiest, early stages of development. The firm will help its portfolio companies with experienced management, scientists, consultants, and investors.
The fund is interested in early-stage bioscience and therapeutics area including Autoimmune diseases and Immunology, Biofuels, Cancer, Cardiovascular Research, Glycobiology and Carbohydrates, Infectious Disease and Microbiology, Natural Products for Health, Vision Research. The firm is interested in companies in in development to pre-clinical stage.
The fund has no management team requirements and will work with entrepreneurs of all experience levels coming from academia or industry, and has no restriction on the geographic location of companies or technologies.
If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply